Elase-chloromycetin Purple Book BLA 050294
- BLA number
- 050294
- Proprietary names
- Elase-chloromycetin
- Proper names
- fibrinolysin and desoxyribonuclease combined [bovine], with chloramphenicol
- Applicant
- Parke-Davis, a Division of Pfizer Inc.
- Center
- CDER
- First observed release
- 2020-05-01
- Latest observed release
- 2026-06-01
- Newest archive release
- 2026-06-01
- FDA patent list
- No patents listed in the captured FDA patent list; source updated 2025-06-11
- Coverage
- Present in newest release
Latest Known Product Presentations#
Product, Proprietary name, Proper name table| Product | Proprietary name | Proper name | License type | Strength | Dosage form | Route | Presentation | Marketing | Licensure | Approval | Patent list provided |
|---|
| 001 | Elase-chloromycetin | fibrinolysin and desoxyribonuclease combined [bovine], with chloramphenicol | 351(a) | 10MG/GM; 666UNITS/GM; 1UNIT/GM | Ointment | Topical | Tube | Disc | Voluntarily Revoked | 1964-04-01 | |
Published Patent List#
No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.
Official Monthly Change Events#
Release, Event, Product table| Release | Event | Product | Name | License type | Status | Applicant |
|---|
| 2021-07-01 | U | 001 | Elase-chloromycetin | 351(a) | Disc | Parke-Davis, a Division of Pfizer Inc. |
| 2021-06-01 | U | 001 | Elase-chloromycetin | 351(a) | Disc | Parke-Davis, a Division of Pfizer Inc. |
| 2020-05-01 | R | 001 | Elase-chloromycetin | 351(a) | Disc | Parke-Davis, a Division of Pfizer Inc |
Observed Product State History#
Release, Product, Name table| Release | Product | Name | License type | Marketing | Licensure | Approval |
|---|
| 2021-07-01 | 001 | Elase-chloromycetin | 351(a) | Disc | Voluntarily Revoked | 1964-04-01 |
| 2020-05-01 | 001 | Elase-chloromycetin | 351(a) | Disc | Licensed | 1964-04-01 |